Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Given the extensive physiological functions and drug development potential of GLP-1R, targeting GLP-1R has become one of the important approaches in treating obesity
STEP 1 (Wilding 2021, NEJM) showed 14.9 percent average weight loss with semaglutide at 68 weeks
While this poses challenges for manufacturers, it also creates novel opportunities for innovation in product development, marketing, and nutrition-focused products
GLP-1 drugs prescribed to treat type 2 diabetes and obesity could reduce the chances of developing acute pancreatitis
Furthermore, recent findings reveal that alterations in BBB and its transporters affect the entry of therapeutic drugs designed to treat neurodegenerative diseases (Zhang, 2025)
of whether the effects of Akkermansia are limited by baseline levels and provides a discernment between natural Akkermansia growth and supplementations effects proven by other studies
US$ 26.46
US$ 21.58
US$ 21.76
US$ 21.76
